BrainStorm Cell Therapeutics Appoints Alon Natanson as Chief Executive Officer
News Jan 29, 2013
“Adrian Harel has led BrainStorm through a transforming period in the company’s history, both in terms of our clinical achievements as well as our financial security. We are pleased that he will be continuing to serve the company, albeit in a different capacity,” said Professor Avi Israeli, Chairman of the Board of Directors.
Prior to joining BrainStorm, Mr. Natanson, 49, successfully led large as well as early-stage companies in the fields of life science, high-tech, and retail. Previously, as Director of Marketing and Finance in Teva Pharmaceuticals’ Copaxone division, he played a key role in the commercialization of patented therapeutics for multiple sclerosis, establishing the division and executing its international strategy and product launch. Mr. Natanson has also led the successful turnaround of two insolvent American retail companies, transforming them into growing organizations with substantial gross margins. Since 2008, he served as President and CEO of Procognia.
“We are delighted to have Alon Natanson on board and warmly welcome him to BrainStorm,” added Professor Israeli. “We have full confidence in his leadership abilities to steer the company to successful completion of clinical development, regulatory approval and commercialization of our technology.”
“BrainStorm’s remarkable achievements to date demonstrate the company’s excellent scientific team and the huge potential of their technology,” commented Mr. Natanson. “I am excited to join the company at this critical stage, as its breakthrough stem cell candidate gets closer to becoming a part of tomorrow’s medicine.”
Scleroderma Study Offers New Hope For SufferersNews
An unusual autoimmune disease that causes skin and lung damage can be treated effectively by stem cell transplant, a new study found. The approach could represent the first new treatment to improve survival in patients with severe scleroderma in more than four decades.READ MORE